Citibank's View of Roche's TIGIT
TIGIT. We Totally Dig It….. Upgrading to Buy
After several false dawns with other ICI (immune checkpoint inhibitors) and TME modifying agents, we believe that tiragolumab (inhibiting TIGIT) could be the first checkpoint to convincingly demonstrate potential additive/synergistic efficacy to PDx therapies across a broad array of solid and liquid tumors.
Sorry this area of the site is available to contributors and subscribers only.
If you're not yet a subscriber why not join today?
If you are already a subscriber, please login.
If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
